ACADIA Pharmaceuticals Inc. ( (ACAD) ) has released its Q4 earnings. Here is a breakdown of the information ACADIA Pharmaceuticals Inc. presented to its investors.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company specializing in developing and commercializing innovative medicines to address unmet medical needs in central nervous system disorders. The company is known for its FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome.
Acadia Pharmaceuticals reported robust financial results for the fourth quarter and full year 2024, with total net product sales reaching $957.8 million, marking a 32% increase in revenue. The company highlighted strong performances from its key products, DAYBUE and NUPLAZID, and outlined strategic initiatives for continued growth in 2025.
The company recorded DAYBUE’s net product sales at $96.7 million for the fourth quarter and $348.4 million for the full year, reflecting a 97% increase from the previous year. NUPLAZID also showed significant growth, with fourth-quarter sales of $162.9 million and full-year sales of $609.4 million, up 11% year-over-year. Acadia’s strategic plans include expanding its DAYBUE field force in the U.S. and building a commercial team in the EU, anticipating the launch of trofinetide there.
Acadia’s financial guidance for 2025 projects total revenues between $1.03 billion and $1.095 billion, with expected increases in both DAYBUE and NUPLAZID sales. The company also plans to advance its clinical pipeline, including studies in Prader-Willi syndrome and Alzheimer’s disease psychosis, aiming for key milestones in 2026.
Looking ahead, Acadia Pharmaceuticals is poised for continued growth, driven by its strategic investments in product commercialization and clinical development. The company remains focused on expanding its market presence and advancing its pipeline to address critical needs in neuroscience and neuro-rare diseases.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com